Starling Oncology (STLN) Q2 2026 earnings review
Profitability Reached, but Mix Shift Requires Scrutiny
Starling Oncology delivered a milestone quarter, driving revenue up 34.6% YoY to $161.3M and turning Adjusted EBITDA positive ($229K). The company subsequently raised full-year revenue and gross profit guidance. However, the quality of this revenue is shifting dramatically. High-margin Fee-For-Service (FFS) revenue is shrinking rapidly, forcing the Specialty Pharmacy segment (+58% YoY) and lower-margin Capitated contracts to do all the heavy lifting for the bottom line.
🐂 Bull Case
Adjusted EBITDA flipped to positive $229K from a $4.1M loss a year ago. H1 Free Cash Flow also rebounded powerfully to $9.5M (from negative $14.6M).
Achieved exclusivity in California with a major partner, adding 230,000 capitated lives, and signed first delegated contracts outside Florida in Nevada and Oregon.
🐻 Bear Case
FFS revenue dropped 16.7% YoY to $30.8M. This segment's decline acts as a severe drag on Patient Services margins.
The Medical Loss Ratio (MLR) on capitated contracts surged to 85.5% from 71.0% YoY, reflecting the margin pressure of onboarding large, immature patient cohorts.
⚖️ Verdict: ⚪
Cautiously Bullish. The headline turnaround to positive EBITDA and cash flow is excellent, but investors must monitor the collapsing FFS segment and the spiking MLR to ensure the capitated growth model doesn't destroy gross margins long-term.
Key Themes
Specialty Pharmacy is the Growth Engine
Accelerating. The Specialty Pharmacy segment remains STLN's most critical financial pillar. Q2 revenue surged 58% YoY to $98.6M, driven by record Part D fills. As new capitated lives are brought onto the platform, STLN is successfully capturing their prescription volumes, providing a massive buffer to overall gross profits.
Capitated Network Expansion
Accelerating. STLN cemented a major exclusivity deal in California, adding ~230,000 capitated lives. Furthermore, they signed their first delegated contracts in Nevada and Oregon. This resulted in Q2 Capitated Revenue jumping 48.5% YoY to $28.0M.
Fee-For-Service (FFS) Collapse
Decelerating. FFS is STLN's clear laggard. Despite management previously labeling FFS declines as 'minor cannibalization', Q2 FFS revenue plunged 16.7% YoY to $30.8M (worsening from a 10% decline in Q1). Because FFS natively carries higher margins, its erosion directly pressures Patient Services gross profitability.
Medical Loss Ratio (MLR) Spikes on New Cohorts
Reversing. STLN's MLR on capitated contracts shot up to 85.5% in Q2, compared to 71.0% a year ago. Direct costs for capitated patients surged 78.7% YoY, significantly outpacing the 48.5% revenue growth. While management expects newly delegated contracts to run higher initially, this exact data point contradicts the narrative of effortless margin expansion.
Starling Nexus Portal Launch
Scheduled for mid-August, the proprietary 'Starling Nexus' provider portal aims to tighten clinical pathway adherence among network physicians. If successful, this technology will directly pull down the elevated MLR and could facilitate higher Part D prescription capture for the pharmacy segment.
Macro: Tariff and Trade Vulnerability
Management explicitly warned in their Safe Harbor language that their outlook assumes a stable global market, noting the business would be 'negatively impacted if recent tariff rate increases and exchange rate changes persist'. Given their reliance on specialized oncology drugs, supply chain inflation remains a looming macro risk.
Other KPIs
Reversing. FCF improved massively from a cash burn of $(14.6)M in H1 2025. This was driven by a $24.9M YoY swing in operating cash flow, validating management's prior quarter claims that scale is allowing them to negotiate significantly better vendor and drug procurement terms.
Accelerating. Up 55.2% YoY, vastly outpacing top-line revenue growth of 34.6%. This indicates that despite the MLR spike in patient services, the volume leverage and margin profile of the Specialty Pharmacy segment are more than compensating at the consolidated level.
Guidance
Accelerating. Raised from the previous range of $630-$650 million. The midpoint ($660M) implies continued high-growth momentum, fueled by the newly announced 230k California lives and Nevada/Oregon expansion.
Accelerating. Raised from the prior $97-$107 million range. Suggests management confidence that the Pharmacy margins will hold up and that newly added capitated cohorts will mature and improve their MLR in the second half of the year.
Stable. The range was updated from $0-$9 million. While the floor was raised, the ceiling was lowered, keeping the implied midpoint essentially flat at $4.5 million. This reflects near-term onboarding costs and the MLR drag of integrating the massive new California exclusivity deal.
Accelerating. A sequential step-up from Q2's $229K, as the company absorbs the ramp-up of Florida delegated lives.
Key Questions
Fee-For-Service Floor
With Fee-For-Service revenue declining nearly 17% year-over-year, where does management see the natural floor for this segment, and how much is true cannibalization versus lost market share?
MLR Maturation Curve
The Medical Loss Ratio jumped significantly to 85.5%. What is the exact expected timeline for the new 230,000 California lives to mature and reach the target mid-80s MLR?
Starling Nexus Adoption
How will you measure and report the financial impact of the Starling Nexus portal? Is there a specific target for increased Part D prescription capture among non-employed MSO providers?